- Addict James Cook and the End of the Road
- Hallowed WTC Steel Relics Arrive in Huntington IMAGES
- Akron man in custody in connection with Huntington heroin overdoses
- Rooster's Hosts Princess Night with Mickey and Minnie Mouse IMAGES
- Cars, Dogs, Rides and Eats Celebrated
- Green Fridays, College Colors Day give Herd fans opportunity to show pride in team
- Secretary of State Candidate Mac Warner Announces Friends of Coal Endorsement
- Water Main and Valve Replacement Project to Cause Temporary Water Outage Monday for Rt. 10/Heath Creek Road Area of Barboursville
- West Virginia Supreme Court of Appeals to conduct public session at Marshall
- Nostalgic Images of Ten Forgotten Huntington Venues
Biomedical sciences researcher to present results of clinical trials on personalized chemotherapy
Thursday, June 12, 2014 - 03:21 Updated 2 years ago Special to HNN Provided by Marshall University
He will be discussing the results of clinical trials conducted at the Edwards Comprehensive Cancer Center. The studies tested ChemoID, a cell culture method he developed with colleague Dr. Jagan Valluri to measure the sensitivity of patients' tumors to chemotherapy treatment for lung, brain/spine and breast cancer.
He says more evaluation of the technology is needed, but preliminary tests on a small number of patients found ChemoID 100 percent accurate in predicting which drug is more effective in treating patients affected by brain cancer if the tumor-initiating cancer stem cells were evaluated.
"Oncologists every day face many challenges in determining the best course of therapy for an individual cancer patient," says Claudio. "The basic problem is that patients with similar diagnoses don't always respond to the same chemotherapy. This technology we have developed could help physicians select the appropriate chemotherapy for an individual patient giving them an edge in the fight against cancer."
He says the good news for cancer patients is that ChemoID may make possible personalized treatment by predicting the most effective drug combination to successfully target that specific patient's cancer increasing the chance the drugs will work and perhaps reducing side effects by helping the patient avoid unnecessary drugs.
In addition to presenting his own research at the conference, Claudio will be moderating a session, "Advances in Oncology and Anticancer Research. Cancer Pathology."
Summaries of the research presented at the meeting will be published in the journal Frontiers in Bioscience.